Centre Hospitalier Intercommunal de Creteil | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects	Ear Diseases, Nausea, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Photophobia, Sensation Disorders, Signs and Symptoms, Signs and Symptoms, Digestive, brain disorder, central nervous system disorder, eye disorder, headache disorder, hearing disorder, hyperacusis, hypnic headache, migraine disorder, nervous system disorder, otorhinolaryngologic disease, vision disorder	Recruiting	Phase 3	2026-09-28		NCT05156398
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Recruiting	Phase 2 / Phase 3	2026-09-16		NCT04613596
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide	Chronic Disease, Digestive System Diseases, Disease Attributes, Hepatitis D, Chronic, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, hepatitis, hepatitis D virus infection, liver disorder, viral hepatitis, viral infectious disease	Recruiting	Phase 2 / Phase 3	2026-09-10		NCT07454837
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum	Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, pulmonary large cell neuroendocrine carcinoma, respiratory system disorder, respiratory tract neoplasm	Recruiting	Phase 2	2024-08-02		NCT06393816